• Expanding installed device bases across all product segments
• Driving customer behaviour changes to increase consumables usage
• Enhancing products and developing next-gen devices with AI and data tools

Universal Biosensors (UBI) is focused on leveraging its advanced electrochemical sensor technology to expand into high-value, global markets. Its long-term strategy revolves around scaling its core business units (Sentia, Xprecia, Petrackr, and AQUASCOUT), driving adoption of consumables (test strips), broadening market reach through partnerships and digital channels, and enhancing technology leadership through continuous innovation. Key pillars of UBI's strategy include increasing market penetration, driving consumables utilization growth, maintaining technology leadership, geographic expansion, strategic partnerships, and e-commerce/DTC growth. While adoption has been slower than expected due to various factors, UBI is confident in the prospects for the future. The company is addressing common shareholder concerns, including Xprecia sales growth, Sentia sales growth, and competitive barriers. To manage its cash position, UBI is prioritizing key growth opportunities, driving cost and cash optimization initiatives, and assessing funding options. Looking ahead, UBI is well-positioned to capitalize on its disruptive technologies, leveraging its direct sales approach, e-commerce expansion, and strategic partnerships to accelerate growth and solidify its position as a global leader in advanced electrochemical diagnostic solutions.

UBI is well-positioned to capitalize on its disruptive technologies, leveraging its direct sales approach, e-commerce expansion, and strategic partnerships to accelerate growth. The company expects strong momentum in 2025 and beyond as Xprecia gains traction in the U.S., Sentia continues to penetrate the global wine industry, and Petrackr enters major e-commerce platforms.